Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point.
Vaxart（納斯達克：VXRT）股票在週五盤前交易中上漲超過23％，一度超過流通時高點。
Vaxart's average session volume was about 1.6 million. Friday premarket's session volume had exceeded four million at the time of writing.
Vaxart的平均交易量約爲160萬。週五盤前交易時段的成交量已超過400萬。
Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services.
昨天，Vaxart通過“快速應對夥伴關係車輛”獲得了價值4.53億美元的項目獎勵，該項目得到了美國衛生與公共服務部（HHS）戰略準備和應對管理局支持的生物醫學先進研發局的支持。
The funding from the award will be disbursed in two installments, with an initial sum of about $65.7 million accessible immediately to facilitate ongoing study start-up endeavors.
來自該獎項的資金將分兩次撥付，首筆約6570萬美元可立即使用以促進正在進行的研究啓動工作。
These funds are designated for conducting a Phase 2b comparative study, which will assess Vaxart's oral pill COVID-19 vaccine candidate against an FDA-approved mRNA vaccine comparator.
這些資金專用於進行2b期比較研究，將評估Vaxart的口服COVID-19疫苗候選藥物與FDA批准的mRNA疫苗比較器進行比較。
Vaxart expects to commence enrollment as soon as summer 2024, with a potential interim analysis of vaccine efficacy compared to an approved mRNA comparator by the first quarter of 2025.
Vaxart預計最快於2024年夏季開始招募，到2025年第一季度可能會對疫苗有效性與批准的mRNA比較器進行中期分析。
This funding from BARDA will assist us in determining whether we can bring a transformational, next-generation approach to global vaccination," said Steven Lo, Vaxart's Chief Executive Officer.
“BARDA的這筆資金將有助於我們確定是否可以將全球疫苗接種引入變革，”Vaxart首席執行官Steven Lo表示。
That's not all!
這還不是全部！
Vaxart also announced an underwritten offering of 50 million shares of its common stock at an offering price of $0.80 per share. This represents a premium of over 6% to the last closing price of $0.75 per share.
Vaxart還宣佈發行5000萬股普通股的認購價爲0.80美元/股的認購書，這相當於每股0.75美元的上一個收盤價格的溢價超過6％。
The offering by Vaxart is anticipated to generate gross proceeds of approximately $40 million prior to deductions for underwriting discounts, commissions, and estimated offering expenses.
Vaxart的發行預計將在扣除承銷折扣，佣金和估計的發行費用之前產生約4000萬美元的募集資金。
It is projected to conclude around June 17, 2024, pending standard closing conditions.
預計將在標準結算條件下於2024年6月17日左右結束。
Price Action: VXRT shares are trading lower by 7.68% to $0.69 at last check on Friday.
股價走勢：截至上週五最後一次查詢，VXRT股價下跌7.68％至0.69美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.November 18th, 2023
免責聲明本內容部分由人工智能工具生成，並經Benzinga編輯審核和發佈。2023年11月18日
譯文內容由第三人軟體翻譯。